Invega (Paliperidone) Drug Information: Medication Guide and Patient Information

Pill Identifier Search

May 27, 2012

Invega

Schizoaffective Disorder »

Introduction

Schizoaffective disorder is a serious mental illness that has features of two different conditions, schizophrenia and an affective (mood) disorder, either major depression or bipolar disorder.

Schizophrenia is a brain disorder that distorts the way a person thinks, acts, expresses emotions, perceives reality and relates to others. Depression is an illness that is marked by feelings of sadness, worthlessness or hopelessness, as well as problems concentrating and remembering details. Bipolar disorder is characterized by cycling mood changes, including severe highs (mania) and lows (depression).

Schizoaffective disorder is a life-long illness that can impact all areas of daily living, including work or school, social contacts and relationships. Most people with this illness have periodic episodes, called relapses, when their symptoms surface. While there is no cure for schizoaffective disorder, symptoms of...

Read the Schizoaffective Disorder article »

« Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
Next »

Invega User Reviews >>

Invega

Schizophrenia Slideshow Pictures

Take the Schizophrenia Quiz

font size

PATIENT INFORMATION

Physicians are advised to discuss the following issues with patients for whom they prescribe INVEGA® (paliperidone) .

Orthostatic Hypotension

Patients should be advised that there is risk of orthostatic hypotension, particularly at the time of initiating treatment, re-initiating treatment, or increasing the dose [see WARNINGS AND PRECAUTIONS].

Interference with Cognitive and Motor Performance

As INVEGA® (paliperidone) has the potential to impair judgment, thinking, or motor skills, patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that INVEGA® (paliperidone) therapy does not affect them adversely [see WARNINGS AND PRECAUTIONS].

Pregnancy

Patients should be advised to notify their physician if they become pregnant or intend to become pregnant during treatment with INVEGA® [see Use in Specific Populations].

Nursing

Caution should be exercised when INVEGA® (paliperidone) is administered to a nursing woman. The known benefits of breastfeeding should be weighed against the unknown risks of infant exposure to paliperidone. [See Use In Specific Populations].

Concomitant Medication

Patients should be advised to inform their physicians if they are taking, or plan to take, any prescription or over-the-counter drugs, as there is a potential for interactions [see DRUG INTERACTIONS].

Alcohol

Patients should be advised to avoid alcohol while taking INVEGA® [see DRUG INTERACTIONS].

Heat Exposure and Dehydration

Patients should be advised regarding appropriate care in avoiding overheating and dehydration [see WARNINGS AND PRECAUTIONS].

Administration

Patients should be informed that INVEGA® (paliperidone) should be swallowed whole with the aid of liquids. Tablets should not be chewed, divided, or crushed. The medication is contained within a nonabsorbable shell designed to release the drug at a controlled rate. The tablet shell, along with insoluble core components, is eliminated from the body; patients should not be concerned if they occasionally notice something that looks like a tablet in their stool [see DOSAGE AND ADMINISTRATION].

Last reviewed on RxList: 5/19/2011
This monograph has been modified to include the generic and brand name in many instances.